Kimal will once again be exhibiting at the NIVAS study day in Edinburgh this year where BioFlo technology will be the star of the show on our stand.
Join us on stand 6 to see how the CT-rated BioFloTM PASV PICC with EndexoTM technology can make a real difference to your patients with its pressure activated safety valves which are clinically proven to reduce catheter occlusions by up to 78% and catheter-related infections by 24%. 1
You can also ask one of our sales team about improving your dialysis flow rates with BioFlo DuraMaxTM; featuring Endexo technology BioFlo DuraMax is proven to minimise thrombus accumulation and improve long-term catheter patency. 21Burns, D. (n.d.) Retrospective Analysis The Vanderbilt PICC service: Program, Program, Procedural and Patient Outcomes Success, Vanderbilt University. JAVA Vol.10 No. 420052The reduction in thrombus accumulation (based on platelet count) is supported by acute in-vitro testing. Pre-clinical in-vitro evaluations do not necessarily predict clinical performance with respect to thrombus formation. Based on benchtop testing up to two hours using bovine blood which may not be indicative of clinical results.